Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index; 5 of the 28 sources its claims cite were checked for support.
Abstract
De novo mutations affect risk for many diseases and disorders, especially those with early-onset. An example is autism spectrum disorders (ASD). Four recent whole-exome sequencing (WES) studies of ASD families revealed a handful of novel risk genes, based on independent de novo loss-of-function (LoF) mutations falling in the same gene, and found that de novo LoF mutations occurred at a twofold higher rate than expected by chance. However successful these studies were, they used only a small fraction of the data, excluding other types of de novo mutations and inherited rare variants. Moreover, such analyses cannot readily incorporate data from case-control studies. An important research challenge in gene discovery, therefore, is to develop statistical methods that accommodate a broader class of rare variation. We develop methods that can incorporate WES data regarding de novo mutations, inherited variants present, and variants identified within cases and controls. TADA, for Transmission And De novo Association, integrates these data by a gene-based likelihood model involving parameters for allele frequencies and gene-specific penetrances. Inference is based on a Hierarchical Bayes strategy that borrows information across all genes to infer parameters that would be difficult to estimate for individual genes. In addition to theoretical development we validated TADA using realistic simulations mimicking rare, large-effect mutations affecting risk for ASD and show it has dramatically better power than other common methods of analysis. Thus TADA's integration of various kinds of WES data can be a highly effective means of identifying novel risk genes. Indeed, application of TADA to WES data from subjects with ASD and their families, as well as from a study of ASD subjects and controls, revealed several novel and promising ASD candidate genes with strong statistical support.
Overview
CoChat Summary
TL;DR
TADA is a hierarchical Bayesian gene-based method that integrates de novo, inherited transmitted/nontransmitted, and case-control rare variant data to identify disease risk genes. Applied to autism spectrum disorder exome data, it estimates about 1,000 ASD risk genes with average loss-of-function relative risk about 20 and identifies novel candidate genes with greater power than de novo-only or meta-analytic tests.
Key findings
- In simulations, TADA had superior power: for a gene with typical parameter values at type I error 0.001, its power was about fivefold larger than the De Novo and Meta tests; genome-wide at FDR below 10%, TADA identified more than 200 ASD risk genes, versus about 50 for the De Novo test and about 70 for the Meta test.
- Using the model, the authors estimated approximately 1,000 ASD risk genes with an average relative risk of approximately 20 due to LoF mutations; an earlier multi-hit-count analysis gave a plausible range of 550 to 1000 risk genes.
- De novo LoF mutations occurred at about a twofold higher rate in ASD probands than unaffected siblings; de novo probably damaging missense (Mis3) mutations were also higher in probands but less strikingly, while other mutation types showed essentially no difference.
- Applying TADA to combined ASD data, 15 genes met an FDR less than 20%, including all five genes with two de novo LoF mutations and novel candidates such as KATNAL2, CHD8, S100G, DYRK1A, PPM1D, SCN2A, CUL3, DEAF1, BANK1, POGZ, WDR55, FAM91A1, and COL25A1.
Methods
- TADA uses a gene-based likelihood model for rare deleterious mutations acting dominantly, with parameters for mutation rate, allele frequency, and gene-specific relative risk/penetrance; it tests relative risk equal to 1 versus greater than 1 using a Hierarchical Bayes/Empirical Bayes strategy that borrows information across genes and can combine multiple mutation types.
- Data included de novo mutations from 932 ASD families across four whole-exome sequencing studies, transmitted/nontransmitted variants from 641 of those families, and case-control data from the ARRA Autism Sequencing Consortium consisting of 935 ASD subjects and 870 controls; analyses focused on LoF and PolyPhen2 “probably damaging” (Mis3) mutations.
- The authors performed simulations under null and alternative models using estimated ASD genetic parameters, applied TADA to ASD data with Benjamini-Hochberg FDR control, and conducted sensitivity analyses varying mutation rates and the prior average relative risk.
Limitations
- The paper states that genotyping/sequencing errors can bias family and combined data analyses, though it argues the variant calls were carefully validated and harmonized; modeling measurement errors is left for future research. It also notes TADA is a one-sided test powered to detect over-transmitted risk variants, so under-transmission bias is not a major concern.
- The paper cautions that the S100G signal is based on a splice variant common in African populations and should be viewed with caution, and that a C1orf95 signal is likely due to population substructure.
- Evident in the text: the method relies on PolyPhen2 classification and downweighting of missense mutations, and the top-gene list uses an FDR threshold of less than 20%, which is relatively permissive.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
4 Valid · 7 Not valid · 19 Not checked · 80 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The overall inflation of the results due to population stratification is negligible: a modified [7] genomic control factor [10] (see Text S1).”
§ Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes > Results > Analysis of data to identify genes affecting the risk of ASD
What the sources say
- Supportedcites [7] L Liu, 2013, Analysis of Rare, Exonic Variation amongst Subjects with Autism Spectrum Disorders and Population Controls, PLoS Genet source
The Introduction states that for these data 'population structure appears to be corrected for by using principal components analysis'. In Results > Distribution of AASC Data the paper defines exactly the modified genomic control factor the citing sentence points to — lambda-1, 'a variant on the GC principle based on the first quantile (rather than the median) of the p-value distribution', which 'has an expected value of 1 when there is no confounding due to population structure (see Text S1)' — and reports that the observed lambda-1 'is close to the mean of the simulated distribution for all 3 choices of eigen-vectors', that it is 'controlled fairly well in the Baylor and Broad samples individually' with only 'a slight inflation (1.08)' in mega SKAT, and that the test statistics 'follow the null hypothesis quite closely'. The residual elevation of the standard median-based GC factor is explicitly attributed to SKAT p-values biased toward .5, 'an apparent, but uninteresting inflation', not to stratification — so the substance of 'negligible overall inflation from population stratification' is stated here, with the paper's own hedge ('slight inflation' in mega-analysis) being the mildest qualification. (LLM, conf=0.82)
- Not checked yetcites [10] B Devlin, 1999, Genomic control for association studies, Biometrics source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“This allele is common in African populations [40].”
§ Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes > Results > Analysis of data to identify genes affecting the risk of ASD
What the sources say
- Could not verifycites [40] JA Tennessen, 2012, Evolution and functional impact of rare coding variation from deep sequencing of human exomes, Science sourceExperimental — accuracy not yet measured
Our copy of Tennessen et al. (2012) never mentions C1orf95: searches for 'C1orf95', for a variant common/high-frequency in African populations, and for the candidate-gene lists (Impact of natural selection on rare coding variation; Patterns of coding variation by gene and pathway) returned only genome-wide summaries, with named loci limited to HLA, DEFB108B, olfactory receptors and histone genes. The paper reports general population-frequency patterns — 86% of >500,000 SNVs rare (MAF <0.5%), 82% population-specific, and higher diversity in AAs (Abstract; Data generation and variant discovery) — but makes no locus-specific statement about a C1orf95 allele. Nothing in our copy contradicts the claim either, so it cannot be settled from this source. (LLM, conf=0.68)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“the case-control data have been carefully harmonized to minimize batch effects by using stringent quality control filters [7]”
§ Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes > Discussion
What the sources say
- Supportedcites [7] L Liu, 2013, Analysis of Rare, Exonic Variation amongst Subjects with Autism Spectrum Disorders and Population Controls, PLoS Genet source
The Results section, “Harmonizing Calls of Genotype across Sequencing Platforms,” describes increasingly stringent filters used to make the case-control datasets more similar. The Discussion says the authors constructed additional filters to reduce differences in rare-variant distributions between sequencing centers, while cautioning that some heterogeneity could remain after filtering. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we validated TADA using realistic simulations mimicking rare, large-effect mutations affecting risk for ASD and show it has dramatically better power than other common methods of analysis.”
- Also stated in: § Power analysis by simulation · plain
“This comprehensive simulation showed TADA has superior power relative to the other two tests (Figure S3).”
§ Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes > Abstract
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Power analysis by simulation · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“matching the expected with the observed value of , we estimate the the number of ASD risk genes is between 550 to 1000 (Figure 3B).”
§ Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes > Results > Genetic architecture of ASD
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 3 assumptions not shown here.
52 more claims
Create a free account to see all 110 claims and to verify the 23 references still open.
- It may state two separate claims as one. 34
- Probably not a substantial claim. 22
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“TADA genes were defined as a set of 113 ASD genes that were associated with ASD at an FDR < 0.05.”
From A phenotypic spectrum of autism is attributable to the combined effects of rare variants, polygenic risk and sex (2022) · cites this paper as [33]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We applied a rare-variant transmission and de novo association (TADA) test33 to the combined data in this study to define a set of 125 ASD susceptibility (TADA genes) with FDR < 0.05”
From A phenotypic spectrum of autism is attributable to the combined effects of rare variants, polygenic risk and sex (2022) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, the discovery of less penetrant disorders can be empowered by analytical methodologies that integrate both DNMs and rare inherited variants, such as TADA34.”
From Evidence for 28 genetic disorders discovered by combining healthcare and research data (2020) · cites this paper as [34]
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 1×
“We control for the multiple hypothesis testing using the Benjamini-Hochberg procedure [11].”
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194 · cited 5×
“The missense labels are based on predictions from PolyPhen2.”
InfluentialGenomic Control for Association Studies
Devlin, B., & Roeder, K. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00997.x · Cited by 3,162 · cited 1×
“The overall inflation of the results due to population stratification is negligible: a modified [7] genomic control factor [10] lq~1:02 (see Text S1).”
Self-citationVisscher, P. M., Brown, M. A., McCarthy, M. I., & Yang, J. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.11.029 · Cited by 2,425 · cited 1×
“It has proven successful for identifying common variation affecting risk, after sufficient samples had been amassed to ensure variation having modest impact on risk could be detected [12].”
Tackling the widespread and critical impact of batch effects in high-throughput data
Leek, J. T., Scharpf, R. B., Bravo, H. C., Simcha, D., Langmead, B., Johnson, W. E., Geman, D., Baggerly, K., & Irizarry, R. A. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2825 · Cited by 2,196 · cited 1×
“Genotyping/sequencing errors can introduce biases in data analyses, especially those for family data [37,38] and for combining data across multiple heterogeneous studies [39].”
Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations
O’Roak, B. J., Vives, L., Girirajan, S., Karakoc, E., Krumm, N., Coe, B. P., Levy, R., Ko, A., Lee, C., Smith, J. D., et al. (2012) · Nature · doi:10.1038/nature10989 · Cited by 2,165 · cited 7×
“Consider the de novo LoF mutations in N~932 families [1–4].”
InfluentialRate of de novo mutations and the importance of father’s age to disease risk
Kong, A., Frigge, M. L., Masson, G., Besenbacher, S., Sulem, P., Magnusson, G., Gudjonsson, S. A., Sigurdsson, A., Jonasdottir, A., Jonasdottir, A., et al. (2012) · Nature · doi:10.1038/nature11396 · Cited by 2,134 · cited 1×
“A recent study identified an additional de novo protein-changing mutation in CUL3 in ASD probands [27], replicating our finding here.”
De novo mutations revealed by whole-exome sequencing are strongly associated with autism
Sanders, S. J., Murtha, M. T., Gupta, A. R., Murdoch, J. D., Raubeson, M. J., Willsey, A. J., Ercan-Sencicek, A. G., DiLullo, N. M., Parikshak, N. N., Stein, J. L., et al. (2012) · Nature · doi:10.1038/nature10945 · Cited by 2,084 · cited 7×
“For each gene, the total rate of base pair substitutions was estimated using a probability model taking the gene length and base content into account [1].”
InfluentialSelf-citationFunctional impact of global rare copy number variation in autism spectrum disorders
Pinto, D., Pagnamenta, A. T., Klei, L., Anney, R., Merico, D., Regan, R., Conroy, J., Magalhaes, T. R., Correia, C., Abrahams, B. S., et al. (2010) · Nature · doi:10.1038/nature09146 · Cited by 2,013 · cited 1×
“Indeed virtually every discovery for ASD risk genes traces to rare and de novo variants [1–4,16–20].”
Patterns and rates of exonic de novo mutations in autism spectrum disorders
Neale, B. M., Kou, Y., Liu, L., Ma’ayan, A., Samocha, K. E., Sabo, A., Lin, C.-F., Stevens, C., Wang, L.-S., Makarov, V., et al. (2012) · Nature · doi:10.1038/nature11011 · Cited by 1,734 · cited 3×
“Based on computations of expected rates of de novo events as a function of a gene’s exonic length and base pair composition [2], a recent study [1] found that d§2 LoF events for Nv1000 is significant evidence to declare a gene as a risk gene (pv0:05, genomewide).”
Self-citation
Cited by
Items 101–200 of 318
Incorporating Functional Information in Tests of Excess De Novo Mutational Load
Jiang, Y., Han, Y., Petrovski, S., Owzar, K., Goldstein, D. B., & Allen, A. S. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.06.013 · Cited by 35
“All methods that utilize estimates of variant functionality have a higher power than the unweighted Poisson test. fitDNM and TADA-denovo show very similar statistical power, even though the simulation model mimics the weighting scheme used by TADAdenovo.”
MethodInfluentialKim, S.-W., Lee, H., Song, D. Y., Lee, G., Ji, J., Park, J. W., Han, J. H., Lee, J., Byun, H. J., Son, J. H., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01385-6 · Cited by 41
“We further aimed to identify autism-associated genes in autistic females and males separately according to the previous framework with de novo variants [6, 37] (Additional file 1: Fig.”
MethodResultMa, L., Bayram, Y., McLaughlin, H. M., Cho, M. T., Krokosky, A., Turner, C., Lindstrom, K., Bupp, C. P., Mayberry, K., Mu, W., et al. (2016) · Human Genetics · doi:10.1007/s00439-016-1731-1 · Cited by 38
“In combining cases from both GeneDx and Ambry, the probability of identifying 13 individuals with de novo variants in PPP1CB among 5982 trios is 2.49 × 10−13 by a Poisson test and 2.22 × 10−16 by TADA (He et al. 2013).”
MethodInfluentialLinking Autism Risk Genes to Disruption of Cortical Development
García-Forn, M., Boitnott, A., Akpinar, Z., & Rubeis, S. D. (2020) · Cells · doi:10.3390/cells9112500 · Cited by 37
“Beyond the obvious gain in power due to a larger sample size, newer analyses [6,8,41] have further boosted gene discovery by using refined association frameworks that go beyond de novo variation [45] and/or exploiting evolutionary constraint scores [8,46–48].”
BackgroundLiu, Y., Liang, Y., Çiçek, A. E., Li, Z., Li, J., Muhle, R., Krenzer, M., Mei, Y., Wang, Y., Knoblauch, N., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.03.023 · Cited by 35
Self-citationMedial prefrontal cortex circuitry and social behaviour in autism
Mediane, D. H., Basu, S., Cahill, E., & Anastasiades, P. G. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110101 · Cited by 45
A comparative study of the genetic components of three subcategories of autism spectrum disorder
Li, J., Hu, S., Zhang, K., Shi, L., Zhang, Y., Zhao, T., Wang, L., He, X., Xia, K., Liu, C., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0081-x · Cited by 31
“Compared with the chance expectation (n= 11), we observed significant enrichment in 88 genes with PTADA ≤ 0.001, corresponding to a FDR of 0.13 (Supplementary Figure 6).”
MethodInfluentialSelf-citationChen, S., Wang, J., Çiçek, A. E., Roeder, K., Yu, H., & Devlin, B. (2020) · Molecular Autism · doi:10.1186/s13229-020-00386-7 · Cited by 33
“The evidence for genetic association of each gene was quantified by a TADA score, a Bayesian association testing metric that, in a recent instantiation, incorporated pLI score for proteintruncating variant (PTV) and MPC score for missense variant [5, 40].”
MethodSelf-citationDiscovery and Validation of Novel Genes in a Large Chinese Autism Spectrum Disorder Cohort
Wang, J., Yu, J., Wang, M., Zhang, L., Yang, K., Du, X., Wu, J., Wang, X., Li, F. R., & Qiu, Z. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.06.025 · Cited by 31
Hui, K. K., Katayama, Y., Nakayama, K. I., Nomura, J., & Sakurai, T. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.08.001 · Cited by 31
Network assisted analysis to reveal the genetic basis of autism
Liu, L., Lei, J., & Roeder, K. (2015) · The Annals of Applied Statistics · doi:10.1214/15-aoas844 · Cited by 36
Self-citationNovel candidate genes in esophageal atresia/tracheoesophageal fistula identified by exome sequencing
Wang, J., Ahimaz, P. R., Hashemifar, S. S., Khlevner, J., Picoraro, J. A., Middlesworth, W., Elfiky, M. M. A., Que, J., Shen, Y., & Chung, W. K. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-020-0680-2 · Cited by 30
Next-Generation Sequencing in Autism Spectrum Disorder
Sanders, S. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026872 · Cited by 41
“2015) using the “transmitted and de novo association” (TADA) test (He et al. 2013) generates a per-gene false discovery rate (FDR).”
BackgroundMethodSelf-citationLi, J., Jiang, Y. W., Wang, T., Chen, H., Xie, Q. S., Shao, Q., Xia, R., Xia, K., Sun, Z. S., & Wu, J. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102656 · Cited by 26
“For analysis of multiple families, an adjusted TADA (Transmission And De novo Association) model 24 was used to prioritise candidate genes and provide a p value for statistical evidence in sporadic genetic diseases on the basis of extensive annotation.”
BackgroundMethodInfluentialLima, L. D. A., dos Santos, A. C. F., Belangero, S. I., Gadelha, A., Bressan, R. A., Salum, G. A., Pan, P. M., Moriyama, T. S., Graeff‐Martins, A. S., Tamanaha, A. C., et al. (2016) · Scientific Reports · doi:10.1038/srep22851 · Cited by 30
Yuan, B., Wang, M., Wu, X., Cheng, P., Zhang, R., Zhang, R., Yu, S., Zhang, J., Du, Y., Wang, X., et al. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01037-6 · Cited by 28
“We first measured the frequency of de novo and missense variants in each gene with DNMR-SC-subtype data [31], then applied the TADA-Denovo method [32].”
MethodBen‐Reuven, L., & Reiner, O. (2016) · Development Growth & Differentiation · doi:10.1111/dgd.12280 · Cited by 27
“Transcriptome screening and whole-exome sequencing not only expanded the number of genes associated with ASD (Iossifov et al. 2012; Sanders et al. 2012; He et al. 2013), but also further allowed converging associated genes to relevant biological pathways.”
BackgroundCross-Disorder Comparison of Four Neuropsychiatric CNV Loci
Moreno‐De‐Luca, D., Moreno-De-Luca, A., Cubells, J. F., & Sanders, S. (2014) · Current Genetic Medicine Reports · doi:10.1007/s40142-014-0045-7 · Cited by 27
Self-citationLiu, Z., Zhang, N., Zhang, Y., Du, Y., Zhang, T., Li, Z., Wu, J., & Wang, X. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00349 · Cited by 24
“We then used a Bayesian model of the TADA (TADA-Denovo) to prioritize ID risk genes based on extreme mutations and four background DNMRs, and the TADA P-value was adjusted to calculate the q-value (He et al., 2013).”
MethodGene constraint and genotype–phenotype correlations in neurodevelopmental disorders
Betancur, C., & Buxbaum, J. D. (2020) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.05.036 · Cited by 27
Self-citationWang, Y.-C., Wu, Y., Choi, J. Y., Allington, G., Zhao, S., Khanfar, M., Yang, K., Fu, P.-Y., Wrubel, M., Yu, X., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020175 · Cited by 25
“Joint analysis of transmitted variants and DNVs Transmission and de novo association test (TADA), extTADA - TADA is the first method developed to jointly model de novo and transmitted mutations by a hierarchical Bayesian modeling framework - extTADA performs a Markov chain Monte Carlo for the Bayesian analysis - Both…”
MethodNebel, R. A., Kirschen, J., Cai, J., Woo, Y. J., Cherian, K. A., & Abrahams, B. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129270 · Cited by 27
“Results from a meta-analysis of separate exome sequencing data for 2591 individuals from the Simons Simplex Collection [39] (693 carefully phenotyped families with a single autistic child in each) were also reviewed for predicted loss of function variants within AKAP8 and AKAP8L.”
MethodRare X-linked variants carry predominantly male risk in autism, Tourette syndrome, and ADHD
Wang, S., Wang, B., Drury, V., Drake, S., Sun, N., Alkhairo, H., Arbelaez, J., Duhn, C., Genetics), T. I. C. G. (., Bromberg, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43776-0 · Cited by 40
Self-citationBio-collections in autism research
Reilly, J., Gallagher, L., Chen, J. L., Leader, G., & Shen, S. (2017) · Molecular Autism · doi:10.1186/s13229-017-0154-8 · Cited by 28
Shank3B mutant mice display pitch discrimination enhancements and learning deficits
Rendall, A. R., Perrino, P. A., Buscarello, A. N., & FITCH, R. H. (2018) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2018.10.003 · Cited by 27
A Whole-Exome Sequencing Study of Tourette Disorder in a Chinese Population
Zhao, X., Wang, S., Hao, J., Zhu, P., Zhang, X., & Wu, M. (2020) · DNA and Cell Biology · doi:10.1089/dna.2019.4746 · Cited by 24
“Advances in whole-exome sequencing (WES) technologies allowed systematic scanning of genes for de novo variants, which are defined as variants that exist only in the child, at single base rather than kilobase resolution in coding regions (He et al. , 2013; Samocha et al. , 2014).”
Calculating the statistical significance of rare variants causal for Mendelian and complex disorders
Rao, A. R., & Nelson, S. F. (2018) · BMC Medical Genomics · doi:10.1186/s12920-018-0371-9 · Cited by 23
“Another method that calculates the significance of NGS findings, the Transmission And De novo Association test (TADA), is a Bayesian model that combines data from de novo mutations, inherited variants in families, and variants in cases and controls in a population [12].”
MethodHe, Z., Zhang, D., Renton, A. E., Li, B., Zhao, L., Wang, G. T., Goate, A., Mayeux, R. P., & Leal, S. M. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.12.001 · Cited by 22
“It was previously shown that integrating information on variant allele frequencies from population-based data into family-based studies can be useful for association studies of rare variants.(53) Jiang et al.”
BackgroundBrain Organoids: Expanding Our Understanding of Human Development and Disease
Chuye, L. E. B., Dimitri, A. J., Desai, A., Handelmann, C. R., Bae, Y., Johari, P., Jornet, J. M., Klejbor, I., Stachowiak, M. K., & Stachowiak, E. K. (2018) · Results and problems in cell differentiation · doi:10.1007/978-3-319-93485-3_8 · Cited by 25
“Here too, scientists are trying to identify the convergent pathways affected by these mutations (He et al. 2013).”
mTADA is a framework for identifying risk genes from de novo mutations in multiple traits
Nguyen, T.-H., Dobbyn, A. L., Brown, R. C., Riley, B. P., Buxbaum, J. D., Pinto, D., Purcell, S., Sullivan, P. F., He, X., & Stahl, E. A. (2020) · Nature Communications · doi:10.1038/s41467-020-16487-z · Cited by 21
“The method is an extension of our previous work for single traits 10,11 . mTADA estimates the proportion of overlapping risk genes ( π 3 ) between two traits, and then uses this information to infer how many overlapping risk genes exist between two traits.”
BackgroundMethodSelf-citationWang, T., Zhang, Y., Liu, L., Wang, Y., Chen, H., Fan, T., Li, J., Xia, K., & Sun, Z. S. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.03.002 · Cited by 20
Self-citationmirDNMR: a gene-centered database of backgroundde novomutation rates in human
Jiang, Y., Li, Z., Liu, Z., Chen, D., Wu, W., Du, Y., Ji, L., Jin, Z., Li, W., & Wu, J. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1044 · Cited by 22
“In principle, accurate estimates of background DNM rates (DNMRs) for each gene could be used to calculate significantly excess of DNMRs (22).”
BackgroundMethodGenomic resources for the study of neuropsychiatric disorders
Senthil, G., Dutka, T., Bingaman, L., & Lehner, T. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.29 · Cited by 20
He, Z., Zhang, D., Renton, A. E., Li, B., Zhao, L., Wang, G. T., Goate, A., Mayeux, R. P., & Leal, S. M. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.01.029 · Cited by 20
Translating precision medicine for autism spectrum disorder: A pressing need
Pérez‐Cano, L., Azidane, S., Sabido-Vera, R., Sirci, F., Durham, L., & Güney, E. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103486 · Cited by 22
Jia, P., Chen, X., Fanous, A. H., & Zhao, Z. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0154-2 · Cited by 23
Nguyen, H. T., Bryois, J., Kim, A., Dobbyn, A., Huckins, L. M., Muñoz‐Manchado, A. B., Ruderfer, D. M., Genovese, G., Fromer, M., Xu, X., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/135293 · Cited by 20
Self-citationPrkn knockout mice show autistic-like behaviors and aberrant synapse formation
Huo, Y., Lü, W., Tian, Y., Hou, Q., & Man, H. (2022) · iScience · doi:10.1016/j.isci.2022.104573 · Cited by 21
“…CNVs in their genome, suggesting that genomic CNVs could be a cause of ASD and highlighting the genes within the CNV genomic fragments for their relevance to the etiology of ASD (Glessner et al., 2009; He et al., 2013; Levy et al., 2011; Morrow et al., 2008; Pinto et al., 2010; Yin et al., 2016).”
BackgroundInfluentialGenetic advances in neurodevelopmental disorders
Gao, S., Shan, C., Zhang, R., & Wang, T. (2024) · Medical Review · doi:10.1515/mr-2024-0040 · Cited by 31
“By combining DNM with RIVs can also increase the power of identifying NDD genes [30].”
Kofuji, T., Hayashi, Y., Fujiwara, T., Sanada, M., Tamaru, M., & Akagawa, K. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.02.052 · Cited by 18
Qiao, L., Welch, C. L., Hernan, R., Wynn, J., Krishnan, U., Zalieckas, J. M., Buchmiller, T. L., Khlevner, J., De, A., Farkouh‐Karoleski, C., et al. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2024.08.024 · Cited by 16
The Importance of Large-Scale Genomic Studies to Unravel Genetic Risk Factors for Autism
Nóbrega, I. D. S., Silva, A. L. T. E., Yokota-Moreno, B. Y., & Sertie, A. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115816 · Cited by 19
“…which incorporates information from multiple variant classes and produces gene-level measures of evidence for association that can be transformed into a false discovery rate [FDR]—[55]) have been successfully performed to confirm previous results and aid gene and locus discovery in ASD [18,56–60].”
BackgroundResultGuerra, M., Medici, V., Sala, G. L., & Farini, D. (2024) · Cells · doi:10.3390/cells13141176 · Cited by 19
“Using validated statistical approaches, such as TADA [36], susceptibility genes associated with ASD have been identified with high confidence (false discovery rate (FDR) threshold of 10”
MethodExploring the biological role of postzygotic and germinal de novo mutations in ASD
Alonso-González, A., Calaza, M., Amigo, J., González‐Peñas, J., Martínez-Regueiro, R., Fernández‐Prieto, M., Parellada, M., Arango, C., Rodriguez‐Fontenla, C., & Carracedo, Á. (2021) · Scientific Reports · doi:10.1038/s41598-020-79412-w · Cited by 18
Genetic Causes of Autism Spectrum Disorders
Huguet, G., & Bourgeron, T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800109-7.00002-9 · Cited by 20
Olfson, E., Farhat, L. C., Liu, W., Vitulano, L. A., Zai, G. C., Lima, M. O., Parent, J. M., Polanczyk, G. V., Cappi, C., Kennedy, J. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50247-7 · Cited by 20
“This extTADA analysis estimates that 1057 genes (95% CI 219 – 2791) contribute to ADHD risk.”
InfluentialKaplanis, J., Samocha, K. E., Wiel, L., Zhang, Z., Arvai, K. J., Eberhardt, R. Y., Gallone, G., Lelieveld, S. H., Martin, H. C., McRae, J. F., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/258723 · Cited by 20
Autism Spectrum Disorder: The Cerebellum, Genes, and Pathways
D’Mello, S. R. (2025) · Neurology International · doi:10.3390/neurolint17100173 · Cited by 17
“…model composed of a two-stage analysis of de novo and inherited genetic variants, which provides yields greater power to identify risk genes [528], was used to study about 43,000 ASD cases, including ~35,000 new cases identified 60 genes including five new moderate-risk genes ( NAV3 , ITSN1…”
Kopp, N., Climer, S., & Dougherty, J. D. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00301 · Cited by 16
“…essentially tables: tables of SNPs showing tentative association, linkage, or transmission disequilibrium (Ma et al., 2009; Wang et al., 2009; Weiss et al., 2009), or tables of CNVs (Sebat et al., 2007; Marshall et al., 2008; Bucan et al., 2009; Glessner et al., 2009; Pinto et al., 2010; Levy et…”
BackgroundST-Steiner: a spatio-temporal gene discovery algorithm
Norman, U., & Çiçek, A. E. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz110 · Cited by 15
“3 Synaptic and chromatin genes form distinct modules Here, we analyze how genes representing some well-known and predicted biological processes are laid out on the subnetwork shown in Section 3. Supplementary Figure S6 shows how synaptic genes (green), chromatin modeling genes (blue) and cytoskeleton-related genes (pi…”
BackgroundRecent ultra-rare inherited mutations identify novel autism candidate risk genesPreprint
Wilfert, A. B., Turner, T. N., Murali, S. C., Hsieh, P., Sulovari, A., Wang, T., Coe, B. P., Guo, H., Hoekzema, K., Bakken, T. E., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.10.932327 · Cited by 14
“Previous studies (7, 9, 32) have typically performed such analyses by integrating such candidates with DNM-enriched genes as opposed to considering them separately.”
BackgroundFernandez, T. V., Williams, Z. P., Kline, T., Rajendran, S., Augustine, F., Wright, N. R. D., Sullivan, C. A. W., Olfson, E., Abdallah, S. B., Liu, W., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291978 · Cited by 17
Anatomy and Cell Biology of Autism Spectrum Disorder: Lessons from Human Genetics
Kleijer, K. T. E., Huguet, G., Tastet, J., Bourgeron, T., & Burbach, J. P. H. (2017) · Advances in anatomy, embryology and cell biology · doi:10.1007/978-3-319-52498-6_1 · Cited by 13
Whole-genome sequencing identifies novel genes for autism in Chinese trios
Chang, S., Liu, J. J., Zhao, Y., Pang, T., Zheng, X., Song, Z., Zhang, A., Gao, X., Luo, L., Guo, Y., et al. (2024) · Science China Life Sciences · doi:10.1007/s11427-023-2564-8 · Cited by 14
“Based on coding variants from both de novo and inherited, we used the transmitted and de novo association (TADA) model (He et al., 2013) to integrate the coding region variants that are de novo or inherited to stratify associated autosomal genes.”
InfluentialHorizons of psychiatric genetics and epigenetics: where are we and where are we heading?
Abdolmaleky, H. M. (2014) · PubMed Central · Cited by 19
DeepND: Deep multitask learning of gene risk for comorbid neurodevelopmental disorders
Beyreli, İ., Karakahya, O., & Çiçek, A. E. (2022) · Patterns · doi:10.1016/j.patter.2022.100524 · Cited by 14
“…spatiotemporal window of neurodevelopment and its corresponding co-expression network are denoted by the abbreviation for its brain-region cluster followed by the time window of interest, e.g. ‘‘PFC-MSC(1–3)’’ represents interactions among genes in the region PFC-MSC during the time interval [1–3].”
BackgroundMethodAdams, C. J., Conery, M., Auerbach, B. J., Jensen, S. T., Mathieson, I., & Voight, B. F. (2023) · PLoS Genetics · doi:10.1371/journal.pgen.1010807 · Cited by 13
Jia, P., Chen, X., Xie, W., Kendler, K. S., & Zhao, Z. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby085 · Cited by 11
Distinct genetic patterns of shared and unique genes across four neurodevelopmental disorders
Zhang, Y., Wang, R., Liu, Z., Jiang, S., Du, L.-F., Qiu, K., Li, F., Wang, Q., Jin, J., Chen, X., et al. (2020) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32821 · Cited by 16
Dalton, G. D., Siecinski, S. K., Nikolova, V. D., Cofer, G. P., Hornburg, K. J., Qi, Y. P., Johnson, G. A., Jiang, Y., Moy, S. S., & Gregory, S. G. (2024) · Behavioral and Brain Functions · doi:10.1186/s12993-024-00240-3 · Cited by 10
Zhao, Y., Lan, T., Zhong, G., Hagen, J., Pan, H., Chung, W. K., & Shen, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-59937-2 · Cited by 16
“The estimated precision can serve as weights or informative priors in statistical methods like DeNovoWEST 56 or extTADA 62 – 64 to improve the power in risk gene discovery.”
Helm, B. M., Langley, K. G., Spangler, B. B., & Vergano, S. A. S. (2015) · Narrative Inquiry in Bioethics · doi:10.1353/nib.2015.0059 · Cited by 10
“Guilt by association” is not competitive with genetic association for identifying autism risk genes
Gunning, M., & Pavlidis, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-95321-y · Cited by 13
Zhang, Y., Wang, T., Wang, Y., Xia, K., Li, J., & Sun, Z. S. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02377-y · Cited by 10
“PTCHD1 and ARHGEF9 were in two groups, including FDRTADA_combined 0.05 and genes with X-linked hemizygous were also involved in similar biological pathways.”
MethodInfluentialDe novo mutations in folate-related genes associated with common developmental disorders
Luo, T., Li, K., Ling, Z., Zhao, G., Li, B., Wang, Z., Wang, X., Han, Y., Xia, L., Zhang, Y., et al. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.02.011 · Cited by 9
“In line with previous studies [34,35], we used the Transmitted And De novo Association (TADA) model [39] to prioritize candidate genes associated with developmental disorders, and then intersected the prioritized candidate genes with FRGs, which were then defined as candidate disease-associated FRGs.”
MethodHu, C., Wang, Y., Li, C., Mei, L., Zhou, B., Li, D., Li, H., Xu, Q., & Xu, X. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1083779 · Cited by 13
“As one of themost heritablemedical conditions, ASD is associated with over a thousand risk genes (He et al., 2013), of which more than 100 genes and genomic regions meet rigorous statistical thresholds for the correlation with ASD phenotype (Satterstrom et al.”
BackgroundAdvancing precision diagnosis in autism: Insights from large-scale genomic studies
Kim, S.-W., & An, J. (2025) · Molecules and Cells · doi:10.1016/j.mocell.2025.100248 · Cited by 13
“The first application of TADA to the Simons Simplex Collection (SSC) (Fischbach and Lord, 2010) WES dataset led to the identification of 33 ASD-associated genes (False discovery rate, FDR ≤ 0.1) (De Rubeis et al., 2014).”
InfluentialGenetic Approaches to Understanding Psychiatric Disease
Michaelson, J. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0551-x · Cited by 11
VARPRISM: incorporating variant prioritization in tests of de novo mutation association
Hu, H., Coon, H. H., Li, M., Yandell, M. D., & Huff, C. D. (2016) · Genome Medicine · doi:10.1186/s13073-016-0341-9 · Cited by 9
“An alternative approach, adopted by TADA-denovo [13], is to analyze multiple categories of mutations (e.g. LGD and missense) separately, and then combine the Bayes factor of individual analyses.”
BackgroundMethodMonoallelic loss-of-function variants in GSK3B lead to autism and developmental delay
Tan, S., Zhang, Q., Zhan, R., Luo, S., Han, Y., Yu, B., Muss, C., Pingault, V., Marlin, S., Delahaye‐Duriez, A., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02806-z · Cited by 8
“Three probabilistic models (denovolyzeR model [35], CH (Human-chimpanzee) model [36], and TADA [Transmission and De Novo Assoication] model [37]) were applied to evaluate the excess of GSK3B LGD variants in ASD cohorts assuming a background de novo LGD variant rate of 1.8 per exome.”
InfluentialXie, Y., Jiang, W., Dong, W., Li, H., Jin, S. C., Brueckner, M. K., & Zhao, H. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010252 · Cited by 7
“based on the recommendation from the authors [40].”
MethodResultLin, K., Liu, H., & Roeder, K. (2020) · Journal of the American Statistical Association · doi:10.1080/01621459.2020.1738234 · Cited by 9
“These 251 genes with dnLoF mutations are natural candidates to compare our risk genes against since many separate studies found twice as many dnLoF mutations in individuals with ASD than individuals without (Neale et al., 2012; Iossifov et al., 2012; Sanders et al., 2012; O’Roak et al., 2012).”
BackgroundInfluentialSelf-citationKimura, H., Mori, D., Aleksić, B., & Ozaki, N. (2020) · Neuroscience Research · doi:10.1016/j.neures.2020.11.008 · Cited by 7
Cappi, C., Oliphant, M. E., Péter, Z., Zai, G. C., Sullivan, C. A. W., Gupta, A. R., Hoffman, E. J., Virdee, M., Willsey, A. J., Shavitt, R. G., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/127712 · Cited by 7
“rate = Damaging_contrib$estimate[2] * 33828798 * 2, diff.”
InfluentialRuzzo, E. K., Pérez‐Cano, L., Jung, J.-Y., Wang, L.-K., Kashef-Haghighi, D., Hartl, C., Hoekstra, J. N., Leventhal, O., Gandal, M. J., Paskov, K. M., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/338855 · Cited by 7
“Identification of 16 novel ASD risk genes enriched for inherited variation We next used the Transmitted And De novo Association (TADA) test(56) to increase power for gene discovery by combining evidence from rare de novo (DN) or transmitted (inherited) protein-truncating variants (PTVs) and de novo missense variants p…”
MethodZeng, W., Guo, H., Liu, Q., & Wong, W. H. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2419202122 · Cited by 8
“These rare variants, though less frequent, can have substantial impacts on disease risk ( 24 ), and incorporating them could enhance the predictive power of PRS ( 25 , 26 ).”
Deleterious coding variation associated with autism is shared across ancestries
Avila, M. N., Jung, S., Satterstrom, F. K., Fu, J. M., Levy, T., Sloofman, L. G., Klei, L., Pichardo, T., Márquez., D. Y. P., Stevens, C. R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04228-6 · Cited by 13
“TADA 4,27 was performed for three types of inheritance classes: de novo (PTV, MisB, MisA, deletion (DEL) and duplication (DUP)), inherited (PTV, MisB and MisA) and case−control (PTV, MisB, MisA, DEL and DUP) variation.”
Hu, C., He, L., Li, H., Ding, Y., Zhang, K., Li, D., Zhu, G., Wu, B., Xu, X., & Xu, Q. (2022) · Genes · doi:10.3390/genes13061010 · Cited by 8
“Over 1000 genes have been reported to be associated with ASD [7].”
BackgroundNguyen, T.-H., He, X., Brown, R. C., Webb, B. T., Kendler, K. S., Vladimirov, V. I., Riley, B. P., & Bacanu, S. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab067 · Cited by 6
“…zero counts for any variant categories; therefore, DECO uses a hierarchical Bayesian approach to model variant counts as in previous proposed methods [3, 4] in which the main parameter for testing the two hypotheses is the relative risk γ ij l ( H 1 : γ ij l (cid:3)= 1 and H 0 : γ ij l = 1).”
BackgroundMethodSelf-citationConsidering the Genetic Architecture of Hypoplastic Left Heart Syndrome
Belmont, J. W. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9100315 · Cited by 7
“Statistical methods for establishing oligogenic inheritance are being developed in parall l with othe m thods for rare variant association testing [43,44] and suggestive cases have been described [45,46].”
MethodDe novo mutational profile in RB1 clarified using a mutation rate modeling algorithm
Aggarwala, V., Ganguly, A. A., & Voight, B. F. (2017) · BMC Genomics · doi:10.1186/s12864-017-3522-z · Cited by 6
“In addition, our approach differs from existing tools like TADA or Poisson models [12, 20], which are designed to assess the total mutational burden in a gene.”
Dissecting Autism Genetic Risk Using Single-cell RNA-seq DataPreprint
Chen, S., Zhou, X., Byington, E., Bruce, S. L., Zhang, H., & Shen, Y. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.15.153031 · Cited by 5
“Application of A-risk in stratified risk-gene discovery analysis In this analysis, we used an empirical Bayesian model of rare-variant genetic architecture, extTADA (Extended Transmission and de novo Association)[39, 40], which can estimate mean effect sizes and risk-gene proportions from the genetic data to identify…”
MethodShanta, O., Klein, M., Sacks, M., MacDonald, J. R., Maihofer, A. X., Ahangari, M. M., Engchuan, W., Thiruvahindrapuram, B., Guevara, J., Hong, O., et al. (2025) · medRxiv · doi:10.1101/2025.07.11.25331310 · Cited by 16
“The fact that all associations occur within CNV hotspots is consistent with the statistical power for rare variants being greatest for the loci with the highest mutation rates 58 .”
Self-citationLuo, T., Pan, J., Zhu, Y. J., Wang, X., Li, K., Zhao, G., Li, B., Hu, Z., Xia, K., & Li, J. (2023) · QJM · doi:10.1093/qjmed/hcad249 · Cited by 6
“15 for estimators.”
MethodHan, S., Sun, X., Sloofman, L. G., Satterstrom, F. K., Xu, X., Liang, L., Knoblauch, N., Sheng, W., Zhao, S., Nguyen, T.-H., et al. (2025) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2025.11.013 · Cited by 8
Self-citationZhao, T., Zhu, G., Dubey, H. V., & Flaherty, P. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad084 · Cited by 6
The Genetic and Epigenetic Basis Involved in the Pathophysiology of ASD: Therapeutic Implications
Carrascosa-Romero, M. C., & de Cabo, C. (2017) · InTech eBooks · doi:10.5772/66854 · Cited by 6
Caballero, M., Satterstrom, F. K., de Rubeis, S., Buxbaum, J. D., & Mahjani, B. (2026) · Communications Biology · doi:10.1038/s42003-026-10380-z · Cited by 7
“While 1,100 genes are estimated to contribute to ASD risk 11 , only a few hundred have been con fi dently identi fi ed 3,4,6,12 , mostly by considering aggregate variants across a gene and leveraging advanced statistical models such as the Transmission and De Novo Association (TADA) test 13 .”
Self-citationAn Overview of Bioinformatics Methods for Analyzing Autism Spectrum Disorders
Nakashima, S., Nacher, J. C., Song, J., & Akutsu, T. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191111154837 · Cited by 5
The Newly Emerging View of the Genome
Sanders, S., & Mason, C. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800105-9.00001-9 · Cited by 7
Self-citationDon’t Worry, the Genetics of Obsessive-Compulsive Disorder Is Finally Catching Up
Grice, D. E. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.04.011 · Cited by 4
Li, M., Zeng, X. Q., Jin, C., Jin, S. C., Dong, W., Brueckner, M. K., Lifton, R. P., Lu, Q., & Zhao, H. (2021) · Quantitative Biology · doi:10.15302/j-qb-021-0248 · Cited by 5
“The details about hyperparameter estimation for γ were discussed in the TADA model [12].”
MethodResultInfluentialM-DATA: A statistical approach to jointly analyzing de novo mutations for multiple traits
Xie, Y., Li, M., Dong, W., Jiang, W., & Zhao, H. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009849 · Cited by 4
Ng, J. K., Chen, Y., Akinwe, T. M., Heins, H. B., Mehinovic, E., Chang, Y., Payne, Z. L., Manuel, J. G., Karchin, R., & Turner, T. N. (2024) · medRxiv · doi:10.1101/2024.02.02.24302238 · Cited by 4
Substantial role of rare inherited variation in individuals with developmental disordersPreprint
Samocha, K. E., Chundru, V. K., Fu, J. M., Gardner, E. J., Danecek, P., Wigdor, E. M., Malawsky, D. S., Lindsay, S., Campbell, P. H., Singh, T., et al. (2024) · medRxiv · doi:10.1101/2024.08.28.24312746 · Cited by 4
“We applied the Transmission and De Novo Association (TADA) framework 13,25 , a Bayesian analytical framework that makes use of priors on the risk of a given variant class in each gene to measure statistical evidence, which has been successfully applied to studies of the genetic basis of autism…”
BackgroundMethodStriking Departures from Polygenic Architecture in the Tails of Complex TraitsPreprint
Souaiaia, T., Wu, H.-M., Ori, A. P. S., Choi, S., Hoggart, C., & O'Reilly, P. F. (2024) · bioRxiv · doi:10.1101/2024.11.18.624155 · Cited by 4
“This distribution has been used previously to simulate genetic effects in humans and reflects a prior belief in a small number of large effects and many small effects [57] .”
Wang, B., Tran, M. N., Wang, S., Liu, Y., Olfson, E., Wang, G., Sun, N., Dea, J., Olwal, C. O., Bertolace, L., et al. (2025) · medRxiv · doi:10.1101/2025.10.10.25337672 · Cited by 3
“TADA framework for gene discovery: We applied the Transmission and De Novo Association (TADA) test, a Bayesian model that integrates evidence across multiple classes of genetic variation to identify risk genes 42 .”
Self-citationBlack EquaLity in OCD NeuroGenomics ( BELONG ): Study Protocol
Williams, I. J., Márquez., D. Y. P., Lopez-Lengowski, K., Bommiasamy, M., Onyeka, O. “., Underwood, S. J., Avery, J. E., Gluckman, J., Pichardo, T., Chandler, R., et al. (2026) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmgb.70002 · Cited by 3
“At present, the transmitted and de novo (TADA) model (He et al. 2013) allows one to simultaneously analyze de novo, transmitted, and case–control rare variant data.”
Self-citationAcorn: an R package for de novo variant analysis
Turner, T. N. (2023) · BMC Bioinformatics · doi:10.1186/s12859-023-05457-z · Cited by 2
“Several tools exist for step 1 [1-4] and step 3 [5-9].”
MethodBayesian Rare Variant Analysis Identifies Novel Schizophrenia Putative Risk Genes
Han, S. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14080822 · Cited by 4
“In the future, it would be interesting to integrate de novo samples to prioritize SCZ risk genes, like TADA [20], using DeNovoWEST [54], especially when a large number of de novo samples of SCZ become available.”
BackgroundResult
Metadata
- Authors
- He, X., Sanders, S. J., Liu, L., De Rubeis, S., Lim, E. T., Sutcliffe, J. S., Schellenberg, G. D., Gibbs, R. A., Daly, M. J., Buxbaum, J. D., State, M. W., Devlin, B., & Roeder, K.
- Affiliations
- Carnegie Mellon University (US)
- Yale University (US)
- Broad Institute (US)
- Vanderbilt University (US)
- University of Pennsylvania (US)
- Baylor College of Medicine (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Pittsburgh (US)
- Corresponding author
- Roeder, Kathryn
- ORCID
- Venue
- PLoS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-08-15
- Volume
- 9
- Issue
- 8
- Pages
- e1003671
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- PMC
- PMC3744441
- OpenAlex
- W2125226755
- Semantic Scholar
- 041f0c3d75072dec83d95d6bbf32c4757308d641
- Cited by
- 304
- References
- 42
- Citations by year
- 2026: 18 · 2025: 23 · 2024: 29 · 2023: 18 · 2022: 23 · 2021: 31 · 2020: 25 · 2019: 24 · 2018: 26 · 2017: 23 · 2016: 27 · 2015: 21 · 2014: 15 · 2013: 1
- FWCI
- 14.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Genetics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- D-Scholarship@Pitt (University of Pittsburgh) (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Figshare (submittedVersion, cc-by)
- Funders
- Autism Speaks
- Simons Foundation
- Simons Foundation Autism Research Initiative
- National Institutes of Health (MH057881)
- National Institute of Mental Health (U01MH100209, R01MH061009, R01MH089025, U01MH100229, MH089004, MH089025, R01MH089175, R01MH089004, R37MH057881, R01MH089208, U01MH100239, R01MH057881, MH089482, MH057881, R01MH089482, MH061009, U01MH100233)
- National Human Genome Research Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Keywords
- de novo mutations, autism spectrum disorder, TADA, Bayesian hierarchical model, penetrance, allele frequency, exome sequencing
- MeSH terms
- Bayes Theorem, Child Development Disorders, Pervasive, Humans, Models, Theoretical, Mutation, Risk Factors, Genetic Variation, Likelihood Functions, Case-Control Studies, Sequence Analysis, DNA, Genetic Predisposition to Disease, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.